<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01646320</url>
  </required_header>
  <id_info>
    <org_study_id>MB102-129</org_study_id>
    <secondary_id>2011-006324-20</secondary_id>
    <nct_id>NCT01646320</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Dapagliflozin in Triple Therapy to Treat Subjects With Type 2 Diabetes</brief_title>
  <official_title>A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy of Therapy With Dapagliflozin Added to Saxagliptin in Combination With Metformin Compared to Therapy With Placebo Added to Saxagliptin in Combination With Metformin in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin and Saxagliptin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to learn if BMS-512148 (Dapagliflozin) as part of a triple
      combination therapy can improve (decrease) hemoglobin A1c in patients with type 2 diabetes
      after 24 weeks of treatment compared to a 2 drug oral antidiabetic therapy. The safety of
      this treatment will also be studied.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prior to randomization, all eligible subjects will receive open-label treatment with
      Saxagliptin 5mg and Metformin IR during the 16-week open-label treatment period.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2012</start_date>
  <completion_date type="Actual">February 2015</completion_date>
  <primary_completion_date type="Actual">August 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adjusted Mean Change From Baseline in Hemoglobin A1C (HbA1c) at Week 24</measure>
    <time_frame>From Baseline to Week 24</time_frame>
    <description>HbA1c was measured as percent of hemoglobin by a central laboratory. Data after rescue medication was excluded from this analysis. Baseline was defined as the last assessment prior to the start date and time of the first dose of the double-blind study medication. In cases where time of the first dose or time of the assessment was not available, baseline was defined as the last assessment on or prior to the date of the first dose of the double-blind study medication. HbA1c measurements were obtained during the qualification and lead-in periods and on Day 1 and Weeks 6, 12, 18, and 24 in the double-blind period.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adjusted Mean Change From Baseline in Fasting Plasma Glucose at Week 24</measure>
    <time_frame>From Baseline to Week 24</time_frame>
    <description>Data after rescue medication was excluded from this analysis. Baseline was defined as the last assessment prior to the start date and time of the first dose of the double-blind study medication. In cases where time of the first dose or time of the assessment was not available, baseline was defined as the last assessment on or prior to the date of the first dose of the double-blind study medication. FPG measurements were obtained during the qualification and lead-in periods and on Day 1 and Weeks 6, 12, 18, and 24 in the double-blind period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adjusted Mean Change From Baseline in 120-minute Postprandial Glucose (PPG) at Week 24</measure>
    <time_frame>From Baseline to Week 24</time_frame>
    <description>2-hour postprandial glucose (PPG) from a liquid meal tolerance test (2-h MTT) Subject must be fasted for at least 8 hrs prior to the MTT.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adjusted Mean Change From Baseline in Body Weight at Week 24</measure>
    <time_frame>From baseline to Week 24</time_frame>
    <description>Data after rescue medication was excluded from this analysis. Baseline was defined as the last assessment prior to the start date and time of the first dose of the double-blind study medication. In cases where time of the first dose or time of the assessment was not available, baseline was defined as the last assessment on or prior to the date of the first dose of the double-blind study medication. Body weights were measured during the qualification and lead-in periods and on Day 1 and Weeks 6, 12, 18, and 24 in the double-blind period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects Achieving a Therapeutic Glycemic Response (Hemoglobin A1c [HbA1C]) &lt;7.0% at Week 24 (Last Observation Carried Forward [LOCF])</measure>
    <time_frame>From baseline to week 24</time_frame>
    <description>Percent adjusted for baseline HbA1c. Therapeutic glycemic response is defined as HbA1c &lt;7.0%. Data after rescue medication was excluded from this analysis.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">320</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>Arm1: Dapagliflozin (10 mg) + Saxagliptin + Metformin IR</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2: Placebo + Saxagliptin + Metformin IR</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dapagliflozin</intervention_name>
    <description>Tablets, Oral, 10 mg, Once daily, Up to 52 weeks</description>
    <arm_group_label>Arm1: Dapagliflozin (10 mg) + Saxagliptin + Metformin IR</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo matching with Dapagliflozin</intervention_name>
    <description>Tablets, Oral, 0 mg, Once daily, Up to 52 weeks</description>
    <arm_group_label>Arm 2: Placebo + Saxagliptin + Metformin IR</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saxagliptin</intervention_name>
    <description>Tablets, Oral, 5 mg, Once daily, Up to 52 weeks</description>
    <arm_group_label>Arm1: Dapagliflozin (10 mg) + Saxagliptin + Metformin IR</arm_group_label>
    <arm_group_label>Arm 2: Placebo + Saxagliptin + Metformin IR</arm_group_label>
    <other_name>Onglyza</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin immediate release (IR)</intervention_name>
    <description>Tablets, Oral, ≥ 1500 mg, Twice daily, Up to 52 weeks</description>
    <arm_group_label>Arm1: Dapagliflozin (10 mg) + Saxagliptin + Metformin IR</arm_group_label>
    <arm_group_label>Arm 2: Placebo + Saxagliptin + Metformin IR</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          1. Signed Written Informed Consent

               1. Subjects must be willing and able to give signed and dated written informed
                  consent.

          2. Target Population

             For inclusion into Stratum A:

             i) Subjects with T2DM with inadequate glycemic control, defined as central laboratory
             HbA1c ≥ 8.0 and ≤ 11.5% obtained at the screening visit (ie Week -18 visit), on stable
             metformin therapy alone for at least 8 weeks prior to screening visit at a dose ≥ 1500
             mg per day

             For inclusion into Stratum B:

             ii) Subjects with T2DM with inadequate glycemic control, and HbA1c ≥ 7.5 and ≤ 10.5%
             obtained at the screening visit and on stable metformin therapy at a dose ≥ 1500 mg
             per day AND a DPP4 inhibitor at the maximum approved dose for at least 8 weeks prior
             to screening visit.

             b) C-peptide ≥ 1.0 ng/mL (0.34 nmol/L) at screening visit. c) BMI ≤ 45.0 kg/m2 at the
             screening visit.

          3. Age and Reproductive Status

               1. Men and women, aged ≥ 18 years old at time of screening visit.

               2. Women of childbearing potential (WOCBP) must be using an acceptable method of
                  contraception to avoid pregnancy throughout the study in such a manner that the
                  risk of pregnancy is minimized.

               3. WOCBP must have a negative serum or urine pregnancy test within 24 hours prior to
                  the start of investigational product.

               4. Women must not be breastfeeding

               5. Sexually active fertile men must use highly effective birth control if their
                  partners are WOCBP.

        Exclusion Criteria

          1. Target Disease Exceptions

               1. History of diabetes insipidus

               2. Symptoms of poorly controlled diabetes that would preclude participation in this
                  trial including but not limited to marked polyuria and polydipsia with greater
                  than 10% weight loss during the three months prior to screening, or other signs
                  and symptoms.

               3. History of diabetic ketoacidosis or hyperosmolar nonketotic coma.

          2. Medical History and Concurrent Diseases

               1. History of bariatric surgery or lap-band procedure within 12 months prior to
                  screening.

               2. Any unstable endocrine, psychiatric or rheumatic disorders as judged by the
                  Investigator.

               3. Subject who, in the judgment of the investigator, may be at risk for dehydration
                  or volume depletion that may affect the interpretation of efficacy or safety data
                  and concomitant use of loop diuretics in countries where this is not recognized
                  in the Dapagliflozin label.

               4. Subject is currently abusing alcohol or other drugs or has done so within the
                  last 6 months.

                  Acute Vascular Event:

               5. Uncontrolled hypertension defined as systolic blood pressure (SBP) ≥ 160 mmHg
                  and/or diastolic blood pressure (DBP) ≥ 100 mmHg.

               6. Cardiovascular Disease within 3 months of the screening visit [ie myocardial
                  infarction, cardiac surgery or revascularization (CABG/PTCA), unstable angina,
                  stroke or transient ischemic attack (TIA)].

               7. Congestive heart failure as New York Association (NYHA) class IV, unstable or
                  acute congestive heart failure.

                  Renal Diseases:

               8. Moderate or severe impairment of renal function [defined as eGFR &lt; 60
                  mL/min/1.73m2 (estimated by MDRD) or serum creatinine (Scr) ≥ 1.5 mg/dL in males
                  or ≥ 1.4 mg/dL in females.]

               9. Conditions of congenital renal glucosuria

                  Hepatic Diseases:

              10. Significant hepatic disease, including, but not limited to, chronic active
                  hepatitis and/or severe hepatic insufficiency, including subjects with ALT and/or
                  AST &gt; 3x ULN and or Total Bilirubin &gt; 2.5 x ULN.

                  Hematological and Oncological Disease/Conditions:

              11. History of hemoglobinopathy, with the exception of sickle cell trait (SA) or
                  thalassemia minor; or chronic or recurrent hemolysis.

              12. Malignancy within 5 years of the screening visit (with the exception of treated
                  basal cell or treated squamous cell carcinoma)

              13. Known immunocompromised status, including but not limited to, individuals who
                  have undergone organ transplantation or who are positive for the human
                  immunodeficiency virus.

              14. Donation of blood or blood products to a blood bank, blood transfusion, or
                  participation in a clinical study requiring withdrawal of &gt; 400 mL of blood
                  during the 6 months prior to the screening visit.

                  Prohibited treatment and therapies:

              15. Administration of any antihyperglycemic therapy, other than metformin and DPP4's,
                  for more than 14 days (consecutive or not) during the 12 weeks prior to
                  screening, as well as previous exposure to DPP4 or SGLT-2 inhibitor in any DPP4
                  or SGLT-2 inhibitor trial is an exclusion criterion.

              16. Current treatment with potent cytochrome P450 3A4/5 inhibitors (in countries
                  where dose adjustment would be required by the dapagliflozin label).

              17. Administration of any other investigational drug or participation in any
                  interventional clinical studies within 30 days of planned screening to this
                  study. Subjects who failed to satisfy all eligibility criteria at screening and
                  did not enter the lead-in or open-label period in CV181-168 or CV181-169 studies
                  specifically, do not need to wait 30 days.

          3. Physical and Laboratory Test Findings

             a) Hemoglobin ≤ 11.0 g/dL (110 g/L) for men; hemoglobin ≤ 10.0 g/dL (100 g/L) for
             women

             b) Presence of hematuria:

             i) For male subjects being considered for Stratum A: microscopic hematuria present at
             Week -18 or Week -16 AND no common cause that can be confirmed is exclusionary. Male
             subjects with a confirmed common cause can be entered into the open-label phase with a
             documented negative result for hematuria microscopic urinalysis performed by the
             central laboratory.

             ii) For male subjects being considered for Stratum B: microscopic hematuria present at
             Week -10 or Week -8 AND no common cause that can be confirmed is exclusionary. Male
             subjects with a confirmed common cause can be entered into the open-label phase with a
             documented negative result for hematuria microscopic urinalysis performed by the
             central laboratory.

             NOTE: Female sub}ects with hematuria can be entered into the open-label phase and be
             randomized, but should be investigated according to local standards and best clinical
             practices. (See Appendix 3)

             c) Other central laboratory test findings:

             − Abnormal free T4 values. Abnormal thyroid stimulating hormone (TSH) value at
             screening will be further evaluated by free T4. Sub}ects with abnormal free T4 values
             will be excluded.

               -  Positive for hepatitis B surface antigen

               -  Positive for anti-hepatitis C virus antibody

          4. Allergies and Adverse Drug Reaction

             a) Subjects who have contraindications to therapy as outlined in the dapagliflozin and
             saxagliptin Investigator Brochure, the local dapagliflozin or saxagliptin package
             insert or the local metformin package insert, including current treatment with potent
             cytochrome P450 3A4/5 inhibitors (in countries where dose adjustment would be required
             by the local Onglyza (saxagliptin) label.

          5. Sex and Reproductive Status

             a) Women who are pregnant

          6. Other Exclusion Criteria

               1. Prisoners or subjects who are involuntarily incarcerated

               2. Subjects who are compulsorily detained for treatment of either a psychiatric or
                  physical (eg, infectious disease) illness

               3. Subjects on a commercial weight loss program with ongoing weight loss, or on an
                  intensive exercise program.

               4. Employee of BMS, AstraZeneca (AZ), or their relatives.

               5. Subject with any condition which, in the judgment of the Investigator, may render
                  the subject unable to complete the study or which may pose a significant risk to
                  the subject.

               6. Subject is a participating investigator, study coordinator, employee of an
                  investigator or immediate family member of any of the aforementioned.

                  Open Label Treatment Period

                  Note: Enrollment of subjects into the open-label (Stratum A) treatment period,
                  beginning eee -16 of the study with HbA1c values at the lower bound (≥ 8.0% and ≤
                  9.0%) and Enrollment of subjects into the open-label (Stratum B) eee -8, of the
                  study with HbA1c values at the lower bound (≥ 7.5% and ≤ 8.5%) will be limited to
                  approximately 50% of the total number of subjects randomized.

                  • For subject in Stratum A:

                    -  At Week -10 and Week -2 a FPG qualification check will be performed.
                       Subjects with a central laboratory FPG value meeting &gt; 270 mg/dL will be
                       scheduled for a follow-up visit (within 3 - 5 days) to obtain a second
                       central laboratory FPG value. If the mean of the originally scheduled
                       central laboratory FPG and the repeat central laboratory FPG value is &gt; 270
                       mg/dL, the subject cannot be randomized and must be discontinued.

                         -  For subjects in Stratum B:

                    -  At Week -2 a FPG qualification check will be performed. Subjects with a
                       central laboratory FPG value meeting &gt; 270 mg/dL will be scheduled for a
                       follow-up visit (within 3 - 5 days) to obtain a second central laboratory
                       FPG value. If the mean of the originally scheduled central laboratory FPG
                       and the repeat central laboratory FPG value is &gt; 270 mg/dL, the subject
                       cannot be randomized and must be discontinued

                  Double Blind Treatment Period

                  Inclusion criteria:

                  • For Stratum A AND Stratum B:

                  − Subjects with T2DM with inadequate glycemic control, defined as central
                  laboratory HbA1c ≥ 7.0 and ≤ 10.5% obtained at the Week -2 visit of the
                  open-label treatment period.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Of Alabama At Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Advantage Inc/Desert Clinical Research Llc</name>
      <address>
        <city>Mesa</city>
        <state>Arizona</state>
        <zip>85213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Advantage, Inc.</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85018</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Elite Clinical Studies, Llc</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85018</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arkansas Clinical Research</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Torrance Clinical Research Institute Inc.</name>
      <address>
        <city>Lomita</city>
        <state>California</state>
        <zip>90717</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Randall G. Shue, Do, Inc.</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90023</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Research Institute</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90057</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diabetes Medical Center Of California</name>
      <address>
        <city>Northridge</city>
        <state>California</state>
        <zip>91325</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cassidy Medical Group/Clinical Research Advantage</name>
      <address>
        <city>Vista</city>
        <state>California</state>
        <zip>92083</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Palm Springs Research Institute</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fpa Clinical Research</name>
      <address>
        <city>Kissimmee</city>
        <state>Florida</state>
        <zip>34741</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>International Research Associates, Llc</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33183</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Omega Research Consultants, Llc</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Compass Research East, Llc</name>
      <address>
        <city>Oviedo</city>
        <state>Florida</state>
        <zip>32765</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Palm Harbor Medical Associates</name>
      <address>
        <city>Palm Harbor</city>
        <state>Florida</state>
        <zip>34684</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cedar Crosse Research Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Advantage</name>
      <address>
        <city>Evansville</city>
        <state>Indiana</state>
        <zip>47714</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Associated Internal Medicine Specialists</name>
      <address>
        <city>Battle Creek</city>
        <state>Michigan</state>
        <zip>49015</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jackson Clinic</name>
      <address>
        <city>Rolling Fork</city>
        <state>Mississippi</state>
        <zip>39159</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Premier Research</name>
      <address>
        <city>Trenton</city>
        <state>New Jersey</state>
        <zip>08611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Metrolina Internal Medicine</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sterling Research Grp, Ltd.</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Endocrine Associates</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sam Clinical Research Center</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tidewater Integrated Medical Research</name>
      <address>
        <city>Virginia Beach</city>
        <state>Virginia</state>
        <zip>23454</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Broumov</city>
        <zip>550 01</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Pardubice</city>
        <zip>530 02</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Praha 10</city>
        <zip>100 00</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Praha 4</city>
        <zip>149 00</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Pribram V</city>
        <zip>261 95</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Guadalajara</city>
        <state>Jalisco</state>
        <zip>44670</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Zapopan</city>
        <state>Jalisco</state>
        <zip>45116</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Zapopan</city>
        <state>Jalisco</state>
        <zip>45200</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Monterrey</city>
        <state>Nuevo Leon</state>
        <zip>64060</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Monterrey</city>
        <state>Nuevo Leon</state>
        <zip>64460</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Aguascalientes</city>
        <zip>20127</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Bialystok</city>
        <zip>15-435</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Krakow</city>
        <zip>30-015</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Ruda Slaska</city>
        <zip>41-709</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Warszawa</city>
        <zip>00-465</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Warszawa</city>
        <zip>01-868</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Warszawa</city>
        <zip>03-003</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Zory</city>
        <zip>44-240</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Puerto Rico</name>
      <address>
        <city>San Juan</city>
        <zip>00909</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Bucharest</city>
        <zip>010825</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Bucharest</city>
        <zip>070208</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Constanta</city>
        <zip>900591</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Craiova</city>
        <zip>200349</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Galati</city>
        <zip>800098</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Ploiesti</city>
        <zip>100097</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Kursk</city>
        <zip>305035</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Moscow</city>
        <zip>119034</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Saint-petersburg</city>
        <zip>194044</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>St. Petersburg</city>
        <zip>194044</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>St. Petersburg</city>
        <zip>194156</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>St. Petersburg</city>
        <zip>195257</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>St. Petersburg</city>
        <zip>197136</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>St.petersburg</city>
        <zip>195112</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>St.petersburg</city>
        <zip>197022</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Yaroslaval</city>
        <zip>150062</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Portsmouth</city>
        <state>Hants</state>
        <zip>PO3 6LY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Newport</city>
        <state>Isle of Wight</state>
        <zip>PO30 5TG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Liverpool</city>
        <state>Merseyside</state>
        <zip>L7 8XP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Chippenham</city>
        <state>Wiltshire</state>
        <zip>SN15 1HP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Bedfordshire</city>
        <zip>SG19 3JR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>London</city>
        <zip>W6 7HY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Czech Republic</country>
    <country>Mexico</country>
    <country>Poland</country>
    <country>Puerto Rico</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>India</country>
    <country>Turkey</country>
  </removed_countries>
  <link>
    <url>http://www.bms.com/studyconnect/Pages/home.aspx</url>
    <description>BMS clinical trial educational resource</description>
  </link>
  <link>
    <url>http://www.bms.com/clinical_trials/Pages/Investigator_Inquiry_form.aspx</url>
    <description>Investigator Inquiry form</description>
  </link>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 18, 2012</study_first_submitted>
  <study_first_submitted_qc>July 19, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 20, 2012</study_first_posted>
  <results_first_submitted>March 9, 2016</results_first_submitted>
  <results_first_submitted_qc>March 9, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 11, 2016</results_first_posted>
  <last_update_submitted>May 18, 2016</last_update_submitted>
  <last_update_submitted_qc>May 18, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 22, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Saxagliptin</mesh_term>
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 3 Trial with Dapagliflozin added to Saxagliptin in Combination with Metformin compared to placebo added to Saxagliptin in combination with Metformin in Subjects with Type 2 Diabetes who have Inadequate Glycemic Control on Metformin and Saxagliptin</recruitment_details>
      <pre_assignment_details>Arm1: Dapagliflozin (10 mg) + Saxagliptin + Metformin IR
Arm 2: Placebo + Saxagliptin + Metformin IR</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Dapa+Saxa+Met</title>
          <description>Participants received dapagliflozin, 10 mg, and open-label saxagliptin 5 mg and metformin ≥1500 mg per day for up to 52 weeks</description>
        </group>
        <group group_id="P2">
          <title>Pla+Saxa+Met</title>
          <description>Participants received dapagliflozin matching placebo and open-label saxagliptin 5 mg and metformin ≥1500 mg per day for up to 52 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Short-term Period (Day 1 to Week 24)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="160"/>
                <participants group_id="P2" count="160"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="148"/>
                <participants group_id="P2" count="153"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>No longer meets study criteria</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not reported</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not specified</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Long-term Period (Weeks 24 to 52)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="147"/>
                <participants group_id="P2" count="147"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="141"/>
                <participants group_id="P2" count="140"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Subject no longer meets study criteria</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All randomized subjects who received at least one dose of study medication</population>
      <group_list>
        <group group_id="B1">
          <title>Dapa+Saxa+Met</title>
          <description>Participants received dapagliflozin, 10 mg, and open-label saxagliptin 5 mg and metformin ≥1500 mg per day for up to 52 weeks</description>
        </group>
        <group group_id="B2">
          <title>Pla+Saxa+Met</title>
          <description>Participants received dapagliflozin matching placebo and open-label saxagliptin 5 mg and metformin ≥1500 mg per day for up to 52 weeks</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="160"/>
            <count group_id="B2" value="160"/>
            <count group_id="B3" value="320"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>YEARS</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55.2" spread="8.61"/>
                    <measurement group_id="B2" value="55.0" spread="9.60"/>
                    <measurement group_id="B3" value="55.1" spread="9.10" lower_limit="30" upper_limit="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt; 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="137"/>
                    <measurement group_id="B2" value="132"/>
                    <measurement group_id="B3" value="269"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;= 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="90"/>
                    <measurement group_id="B2" value="84"/>
                    <measurement group_id="B3" value="174"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70"/>
                    <measurement group_id="B2" value="76"/>
                    <measurement group_id="B3" value="146"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>ASIAN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BLACK/AFRICAN AMERICAN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OTHER</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WHITE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="150"/>
                    <measurement group_id="B2" value="147"/>
                    <measurement group_id="B3" value="297"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AMERICAN INDIAN/ALASKA NATIVE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NATIVE HAWAIIAN/OTHER PACIFIC ISLANDER</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Adjusted Mean Change From Baseline in Hemoglobin A1C (HbA1c) at Week 24</title>
        <description>HbA1c was measured as percent of hemoglobin by a central laboratory. Data after rescue medication was excluded from this analysis. Baseline was defined as the last assessment prior to the start date and time of the first dose of the double-blind study medication. In cases where time of the first dose or time of the assessment was not available, baseline was defined as the last assessment on or prior to the date of the first dose of the double-blind study medication. HbA1c measurements were obtained during the qualification and lead-in periods and on Day 1 and Weeks 6, 12, 18, and 24 in the double-blind period.</description>
        <time_frame>From Baseline to Week 24</time_frame>
        <population>The Randomized Subjects Data Set consists of all randomized subjects who received at least one dose of double-blind study medication during the double-blind treatment period.</population>
        <group_list>
          <group group_id="O1">
            <title>Dapa+Saxa+Met</title>
            <description>Participants received dapagliflozin, 10 mg, and open-label saxagliptin 5 mg and metformin ≥1500 mg per day for up to 52 weeks</description>
          </group>
          <group group_id="O2">
            <title>Pla+Saxa+Met</title>
            <description>Participants received dapagliflozin matching placebo and open-label saxagliptin 5 mg and metformin ≥1500 mg per day for up to 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Adjusted Mean Change From Baseline in Hemoglobin A1C (HbA1c) at Week 24</title>
          <description>HbA1c was measured as percent of hemoglobin by a central laboratory. Data after rescue medication was excluded from this analysis. Baseline was defined as the last assessment prior to the start date and time of the first dose of the double-blind study medication. In cases where time of the first dose or time of the assessment was not available, baseline was defined as the last assessment on or prior to the date of the first dose of the double-blind study medication. HbA1c measurements were obtained during the qualification and lead-in periods and on Day 1 and Weeks 6, 12, 18, and 24 in the double-blind period.</description>
          <population>The Randomized Subjects Data Set consists of all randomized subjects who received at least one dose of double-blind study medication during the double-blind treatment period.</population>
          <units>Percentage of glycosylated hemoglobin</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="158"/>
                <count group_id="O2" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.82" spread="0.0686"/>
                    <measurement group_id="O2" value="-0.1" spread="0.0704"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Tested at alpha=0.05</p_value_desc>
            <method>Longitudinal Repeated Measures Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.72</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0964</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.91</ci_lower_limit>
            <ci_upper_limit>-0.53</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adjusted Mean Change From Baseline in Fasting Plasma Glucose at Week 24</title>
        <description>Data after rescue medication was excluded from this analysis. Baseline was defined as the last assessment prior to the start date and time of the first dose of the double-blind study medication. In cases where time of the first dose or time of the assessment was not available, baseline was defined as the last assessment on or prior to the date of the first dose of the double-blind study medication. FPG measurements were obtained during the qualification and lead-in periods and on Day 1 and Weeks 6, 12, 18, and 24 in the double-blind period</description>
        <time_frame>From Baseline to Week 24</time_frame>
        <population>The Randomized Subjects Data Set consists of all randomized subjects who received at least one dose of double-blind study medication during the double-blind treatment period. Number of participants analyzed corresponds to the number of randomized subjects with non-missing baseline value and at least one post-baseline value.</population>
        <group_list>
          <group group_id="O1">
            <title>Dapa+Saxa+Met</title>
            <description>Participants received dapagliflozin, 10 mg, and open-label saxagliptin 5 mg and metformin ≥1500 mg per day for up to 52 weeks</description>
          </group>
          <group group_id="O2">
            <title>Pla+Saxa+Met</title>
            <description>Participants received dapagliflozin matching placebo and open-label saxagliptin 5 mg and metformin ≥1500 mg per day for up to 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Adjusted Mean Change From Baseline in Fasting Plasma Glucose at Week 24</title>
          <description>Data after rescue medication was excluded from this analysis. Baseline was defined as the last assessment prior to the start date and time of the first dose of the double-blind study medication. In cases where time of the first dose or time of the assessment was not available, baseline was defined as the last assessment on or prior to the date of the first dose of the double-blind study medication. FPG measurements were obtained during the qualification and lead-in periods and on Day 1 and Weeks 6, 12, 18, and 24 in the double-blind period</description>
          <population>The Randomized Subjects Data Set consists of all randomized subjects who received at least one dose of double-blind study medication during the double-blind treatment period. Number of participants analyzed corresponds to the number of randomized subjects with non-missing baseline value and at least one post-baseline value.</population>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="158"/>
                <count group_id="O2" value="157"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-32.7" spread="2.821"/>
                    <measurement group_id="O2" value="-5.3" spread="2.968"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Secondary end points are tested following a sequential testing procedure at alpha=0.05</p_value_desc>
            <method>Longitudinal Repeated Measures Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-27.5</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.015</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-35.4</ci_lower_limit>
            <ci_upper_limit>-19.6</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adjusted Mean Change From Baseline in 120-minute Postprandial Glucose (PPG) at Week 24</title>
        <description>2-hour postprandial glucose (PPG) from a liquid meal tolerance test (2-h MTT) Subject must be fasted for at least 8 hrs prior to the MTT.</description>
        <time_frame>From Baseline to Week 24</time_frame>
        <population>The Randomized Subjects Data Set consists of all randomized subjects who received at least one dose of double-blind study medication during the double-blind treatment period. Number of participants analyzed is the number of randomized subjects with non-missing baseline and Week 24 (LOCF) values.</population>
        <group_list>
          <group group_id="O1">
            <title>Dapa+Saxa+Met</title>
            <description>Participants received dapagliflozin, 10 mg, and open-label saxagliptin 5 mg and metformin ≥1500 mg per day for up to 52 weeks</description>
          </group>
          <group group_id="O2">
            <title>Pla+Saxa+Met</title>
            <description>Participants received dapagliflozin matching placebo and open-label saxagliptin 5 mg and metformin ≥1500 mg per day for up to 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Adjusted Mean Change From Baseline in 120-minute Postprandial Glucose (PPG) at Week 24</title>
          <description>2-hour postprandial glucose (PPG) from a liquid meal tolerance test (2-h MTT) Subject must be fasted for at least 8 hrs prior to the MTT.</description>
          <population>The Randomized Subjects Data Set consists of all randomized subjects who received at least one dose of double-blind study medication during the double-blind treatment period. Number of participants analyzed is the number of randomized subjects with non-missing baseline and Week 24 (LOCF) values.</population>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="134"/>
                <count group_id="O2" value="132"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-73.5" spread="4.055"/>
                    <measurement group_id="O2" value="-38.0" spread="4.104"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Secondary end points are tested following a sequential testing procedure at alpha=0.05</p_value_desc>
            <method>Longitudinal Repeated Measures Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-35.5</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.493</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-46.3</ci_lower_limit>
            <ci_upper_limit>-24.7</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adjusted Mean Change From Baseline in Body Weight at Week 24</title>
        <description>Data after rescue medication was excluded from this analysis. Baseline was defined as the last assessment prior to the start date and time of the first dose of the double-blind study medication. In cases where time of the first dose or time of the assessment was not available, baseline was defined as the last assessment on or prior to the date of the first dose of the double-blind study medication. Body weights were measured during the qualification and lead-in periods and on Day 1 and Weeks 6, 12, 18, and 24 in the double-blind period.</description>
        <time_frame>From baseline to Week 24</time_frame>
        <population>The Randomized Subjects Data Set consists of all randomized subjects who received at least one dose of double-blind study medication during the double-blind treatment period</population>
        <group_list>
          <group group_id="O1">
            <title>Dapa+Saxa+Met</title>
            <description>Participants received dapagliflozin, 10 mg, and open-label saxagliptin 5 mg and metformin ≥1500 mg per day for up to 52 weeks</description>
          </group>
          <group group_id="O2">
            <title>Pla+Saxa+Met</title>
            <description>Participants received dapagliflozin matching placebo and open-label saxagliptin 5 mg and metformin ≥1500 mg per day for up to 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Adjusted Mean Change From Baseline in Body Weight at Week 24</title>
          <description>Data after rescue medication was excluded from this analysis. Baseline was defined as the last assessment prior to the start date and time of the first dose of the double-blind study medication. In cases where time of the first dose or time of the assessment was not available, baseline was defined as the last assessment on or prior to the date of the first dose of the double-blind study medication. Body weights were measured during the qualification and lead-in periods and on Day 1 and Weeks 6, 12, 18, and 24 in the double-blind period.</description>
          <population>The Randomized Subjects Data Set consists of all randomized subjects who received at least one dose of double-blind study medication during the double-blind treatment period</population>
          <units>kg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="158"/>
                <count group_id="O2" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.91" spread="0.2191"/>
                    <measurement group_id="O2" value="-0.41" spread="0.2270"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Secondary endpoints are tested following a sequential testing procedure at alpha=0.05</p_value_desc>
            <method>Longitudinal Repeated Measures Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.50</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.3126</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.12</ci_lower_limit>
            <ci_upper_limit>-0.89</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects Achieving a Therapeutic Glycemic Response (Hemoglobin A1c [HbA1C]) &lt;7.0% at Week 24 (Last Observation Carried Forward [LOCF])</title>
        <description>Percent adjusted for baseline HbA1c. Therapeutic glycemic response is defined as HbA1c &lt;7.0%. Data after rescue medication was excluded from this analysis.</description>
        <time_frame>From baseline to week 24</time_frame>
        <population>The Randomized Subjects Data Set consists of all randomized subjects who received at least one dose of double-blind study medication during the double-blind treatment period</population>
        <group_list>
          <group group_id="O1">
            <title>Dapa+Saxa+Met</title>
            <description>Participants received dapagliflozin, 10 mg, and open-label saxagliptin 5 mg and metformin ≥1500 mg per day for up to 52 weeks</description>
          </group>
          <group group_id="O2">
            <title>Pla+Saxa+Met</title>
            <description>Participants received dapagliflozin matching placebo and open-label saxagliptin 5 mg and metformin ≥1500 mg per day for up to 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects Achieving a Therapeutic Glycemic Response (Hemoglobin A1c [HbA1C]) &lt;7.0% at Week 24 (Last Observation Carried Forward [LOCF])</title>
          <description>Percent adjusted for baseline HbA1c. Therapeutic glycemic response is defined as HbA1c &lt;7.0%. Data after rescue medication was excluded from this analysis.</description>
          <population>The Randomized Subjects Data Set consists of all randomized subjects who received at least one dose of double-blind study medication during the double-blind treatment period</population>
          <units>Percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="158"/>
                <count group_id="O2" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.7"/>
                    <measurement group_id="O2" value="13.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Secondary end points are tested following a sequential testing procedure at alpha=0.05</p_value_desc>
            <method>Modified logistic regression</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>25.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>16.7</ci_lower_limit>
            <ci_upper_limit>34.4</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>DAPA + SAXA + MET</title>
          <description>Participants received dapagliflozin, 10 mg, and open-label saxagliptin 5 mg and metformin ≥1500 mg per day for up to 52 weeks</description>
        </group>
        <group group_id="E2">
          <title>PLA + SAXA + MET</title>
          <description>Participants received dapagliflozin matching placebo and open-label saxagliptin 5 mg and metformin ≥1500 mg per day for up to 52 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 17.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="160"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="160"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>THROMBOCYTOPENIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="160"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>ACUTE MYOCARDIAL INFARCTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>ANGINA UNSTABLE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>ATRIAL FIBRILLATION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>CARDIAC FAILURE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>CARDIAC FAILURE ACUTE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>VENTRICULAR TACHYCARDIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="160"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>GASTRIC ULCER</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="160"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>ABSCESS LIMB</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>APPENDICITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>GANGRENE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>POSTOPERATIVE WOUND INFECTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="160"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>ANKLE FRACTURE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="160"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>LIVER FUNCTION TEST ABNORMAL</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="160"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>INVASIVE DUCTAL BREAST CARCINOMA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="160"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>CHRONIC OBSTRUCTIVE PULMONARY DISEASE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="160"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA 17.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="103" subjects_at_risk="160"/>
                <counts group_id="E2" subjects_affected="112" subjects_at_risk="160"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>ABDOMINAL PAIN</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="160"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>DIARRHOEA</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="160"/>
                <counts group_id="E2" events="11" subjects_affected="9" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>DYSPEPSIA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="160"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="160"/>
                <counts group_id="E2" events="9" subjects_affected="8" subjects_at_risk="160"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>CHEST PAIN</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="160"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>HEPATIC STEATOSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="160"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>INFLUENZA</sub_title>
                <counts group_id="E1" events="14" subjects_affected="12" subjects_at_risk="160"/>
                <counts group_id="E2" events="14" subjects_affected="12" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>NASOPHARYNGITIS</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="160"/>
                <counts group_id="E2" events="9" subjects_affected="8" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>PHARYNGITIS</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="160"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>URINARY TRACT INFECTION</sub_title>
                <counts group_id="E1" events="19" subjects_affected="15" subjects_at_risk="160"/>
                <counts group_id="E2" events="19" subjects_affected="16" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>VULVOVAGINAL MYCOTIC INFECTION</sub_title>
                <counts group_id="E1" events="9" subjects_affected="7" subjects_at_risk="160"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="160"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>CONTUSION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="160"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>DYSLIPIDAEMIA</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="160"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>HYPERTRIGLYCERIDAEMIA</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="160"/>
                <counts group_id="E2" events="10" subjects_affected="9" subjects_at_risk="160"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ARTHRALGIA</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="160"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>BACK PAIN</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="160"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>MUSCLE SPASMS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="160"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>MUSCULOSKELETAL PAIN</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="160"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>PAIN IN EXTREMITY</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="160"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="160"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>DIZZINESS</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="160"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" events="16" subjects_affected="11" subjects_at_risk="160"/>
                <counts group_id="E2" events="15" subjects_affected="13" subjects_at_risk="160"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>DEPRESSION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="160"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>COUGH</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="160"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="160"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>RASH</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="160"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Eva Johnsson, Clinical Science Lead</name_or_title>
      <organization>AstraZeneca Pharmaceuticals</organization>
      <phone>+46 31 7762484 ext 762 484</phone>
      <email>Eva.Johnsson@astrazeneca.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

